logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Balázs Dobi

Semmelweis University
H指数:7
被引数:98

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Complex Characterization of Cerebral Vasoreactivity in Internal Carotid Artery Stenotic Patients with Transcranial Doppler Sonography

Pál, H.; Magyar-Stang, R.; Csányi, B.; Gaál, A.; Mihály, Z.; Czinege, Z.; Sótonyi, P.; Horváth, T.; Dobi, B.; Bereczki, D.; et al. 利用经颅多普勒超声对颈内动脉狭窄患者脑血管反应性的综合表征。Life 2025, 15, 1692. [Google Scholar] [CrossRef]

Life
IF3.4
2026-03-030
OAAI
Hanga Pál; Rita Magyar-Stang; Borbála Csányi; Anna Gaál; Zsuzsanna Mihály; Zsófia Czinege; Péter Sótonyi; Tamás Horváth; Balázs Dobi; Dániel Bereczki; Akos Koller; Róbert Debreczeni
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

与最佳可用疗法相比，在既往接受过鲁索利替尼治疗的患者中，使用莫美洛替尼的总体生存率：一项匹配调整的间接比较

Annals of Hematology
IF2.4
2026-02-210
OAAI
Francesca Palandri; Venediktos Kapetanakis; Balázs Dobi; Massimo Breccia; Giuseppe A. Palumbo; Elisabetta Abruzzese; Massimiliano Bonifacio; Mario Tiribelli; Elena Maria Elli; Erika Morsia; Filippo Branzanti; Catherine E. Ellis; Nicholas Ballew; Tom Liu; Kelesitse Phiri; Fulya Sen Nikitas; Shiyuan Zhang; Dwaipayan Patnaik
Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naive chronic lymphocytic leukaemia

泽尼布鲁替尼与固定疗程的维奈克拉和伊布替尼联合方案在初治慢性淋巴细胞白血病患者的疗效和安全性的匹配调整间接比较

BRITISH JOURNAL OF HAEMATOLOGY
IF3.8
2025-11-010
OAAI
Munir, Talha; Mohseninejad, Leyla; Rakonczai, Pal; Dobi, Balazs; Xu, Sheng; Yang, Keri; Vezan, Remus; Calle, Nicolas Martinez
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Zanubrutinib与Venetoclax联合Obinutuzumab在初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的疗效和安全性的间接比较

Oncology and Therapy
IF3.2
2025-09-130
OAAI
Talha Munir; Nicolás Martinez-Calle; Sheng Xu; Keri Yang; Xiaoyun Ge; Ayad K. Ali; Leyla Mohseninejad; Balázs Dobi; Pal Rakonczai; Han Ma; Rhys Williams; Wassim Aldairy; Nicole Lamanna
Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

与最佳可用疗法相比，momelotinib在既往接受过ruxolitinib治疗的患者中的总体生存率：一项匹配调整间接比较研究

BLOOD
IF23.1
2024-11-051
PRE
Palandri, Francesca; Kapetanakis, Venediktos; Dobi, Balazs; Branzanti, Filippo; Ellis, Catherine; Ballew, Nick; Liu, Tom; Phiri, Kelesitse; Sen Nikitas, Fulya; Biasi, Melania; Zhang, Shiyuan; Patnaik, Dwaipayan

研究方向

暂未获取到该数据
R
Rita Magyar-Stang
H 指数:7论文数:16被引数:124
S
Shiyuan Zhang
H 指数:4论文数:51被引数:110
F
Francesca Palandri
H 指数:50论文数:536被引数:9,445
S
Sheng Xu
H 指数:20论文数:124被引数:1,295
T
Talha Munir
H 指数:10论文数:60被引数:792
Z
Zsuzsanna Mihály
H 指数:9论文数:52被引数:483
Z
Zsófia Czinege
H 指数:4论文数:12被引数:78
K
Kelesitse Phiri
H 指数:11论文数:37被引数:427
D
Dániel Bereczki
H 指数:47论文数:355被引数:9,349
L
Leyla Mohseninejad
H 指数:6论文数:67被引数:112